Clinical trials: Cholangiocarcinomas
Hepatocellular Carcinoma, Cholangiocarcinoma, Intrahepatic
Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study
Aim of this prospective national multicenter study is to improve standardization of contrast-enhanced ultrasound (CEUS) in the non-invasive diagnosis of hepatocellular carcinoma (HCC) in high-risk patients.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Intrahepatic, Liver Cirrhosis, Liver Cancer
- Trial name
- ESCULAP (NCT03405909)
- Testing
- contrast enhanced ultrasound (CEUS), MRI, Histology
- Where
- Germany
- Volunteers
- 517 people
- Sponsor
- University Hospital Erlangen
Mesothelioma, Mesothelioma, Malignant
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural
- Trial name
- NCT03907852
- Testing
- gavo-cel, fludarabine, cyclophosphamide
- Where
- 11 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- TCR2 Therapeutics
Biliary Tract Carcinoma, Cholangiocarcinoma
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC).
- Conditions
- Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
- Trial name
- NCT06048133
- Testing
- Gemcitabine, Cisplatin, Zimberelimab
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Nataliya Uboha
Intrahepatic Cholangiocarcinoma (Icc)
Streamlining Radioembolization for Intrahepatic Cholangiocarcinoma
Streamlining TARE for Small IHCC TARE delivers radioactive microspheres (20-60 µm) to tumors via abnormal vasculature, while normal liver sinusoids (<15 µm) block their passage.
- Trial name
- ISTAR-04 (NCT07043348)
- Where
- 4 sites in South Korea
- Volunteers
- 1 people
- Sponsor
- Seoul National University Hospital
Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
This study is designed to 1) select a dose regimen for continued development and 2) evaluate nanvuranlat versus Physicians Best Choice (PBC) (FOLFOX, FOLFIRI, or Best Supportive Care (BSC)) in participants aged 18 years and over…
- Trial name
- Beacon-BTC (NCT07265674)
- Testing
- Nanvuranlat, Physician's Best Choice
- Where
- 18 sites in United States
- Volunteers
- 480 people
- Sponsor
- J-Pharma Co., Ltd.
Cholangiocarcinoma
Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma
1. Primary Objectives (1) To evaluate the safety and tolerability of sacituzumab tirumotecan in combination with pucotenlimab in patients with advanced cholangiocarcinoma; (2) To assess the objective response rate (ORR) of…
- Trial name
- NCT07105852
- Testing
- Sacituzumab tirumotecan (iv)+Putolizumab injection (iv)
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sir Run Run Shaw Hospital
Biliary Tract Neoplasms, Gallbladder Cancer
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
Considering that the poor prognosis of resected biliary tract cancer and negative impact on the survival outcomes of R1/R2 resection, neoadjuvant chemotherapy may improve R0 resection rates and the survival outcomes of patients…
- Conditions
- Biliary Tract Neoplasms, Gallbladder Cancer, Cholangiocarcinoma
- Trial name
- DEBATE (NCT04308174)
- Testing
- Durvalumab + Gem/Cis, Gem/Cis
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Asan Medical Center
Intrahepatic Cholangiocarcinoma (Icc)
Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study
Second-line regimen with or without consolidative radiotherapy in patients with oligometastatic/locally advanced unresectable intrahepatic cholangiocarcinoma: an open-label, randomised, controlled study.
- Trial name
- SED-RO-ICC (NCT06946849)
- Testing
- radiotherapy, FOLFIRI or FOLFOX or Regorafenib
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Shanghai Zhongshan Hospital
Pancreatic Cancer, Cholangiocarcinoma
Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures
Malignant bile duct obstruction is a common sequela of pancreatic cancers or distal bile duct cancers, and its development can hinder the use of chemotherapy, decrease patient quality of life, and decrease survival.
- Trial name
- NCT01721174
- Testing
- SEMS only, EBRFA and SEMS
- Where
- Hong Kong
- Volunteers
- 42 people
- Sponsor
- Chinese University of Hong Kong
Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
The primary objective of this study is to estimate the frequency of FGFR2 fusions in archived intrahepatic cholangiocarcinoma (iCCA) or mixed hepatocellular-cholangiocarcinoma (HCC-CCA) tumor samples
- Conditions
- Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma, Cholangiocarcinoma
- Trial name
- NCT02762721
- Where
- 6 sites in United States, Italy
- Volunteers
- 131 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00059865
- Testing
- gemcitabine hydrochloride, pemetrexed disodium
- Where
- 41 sites in United States
- Volunteers
- 68 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
This is a two arm, open label, multi-center, Phase 2 study to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable Hepatocellular Carcinoma (HCC) or Intra Hepatic Cholangiocarcinoma (ICC) confined to…
- Trial name
- NCT02415036
- Testing
- Delcath Hepatic Delivery System, Melphalan
- Where
- 3 sites in Germany
- Volunteers
- 17 people
- Sponsor
- Delcath Systems Inc.
Morbid Obesity, Vertical Sleeve Gastrectomy
Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma
Increasing rates of highly malignant hepatocellular carcinoma (HCC) and biliary tract cancers (GBTC) observed in Western populations may be related to obesogenic lifestyle factors and their metabolic consequences, such as…
- Conditions
- Morbid Obesity, Vertical Sleeve Gastrectomy, Metabolic Syndrome, Hepatocellular Carcinoma
- Trial name
- METSLIVER (NCT02730611)
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors…
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Trial name
- NCT07458347
- Testing
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 545 people
- Sponsor
- Kestrel Therapeutics, Inc.
Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2…
- Trial name
- FIGHT-302 (NCT03656536)
- Testing
- Pemigatinib, Gemcitabine, Cisplatin
- Where
- 215 sites in United States, Austria and 17 more
- Volunteers
- 167 people
- Sponsor
- Incyte Corporation
Liver Cancer, Intrahepatic Cholangiocarcinoma
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
- Conditions
- Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC
- Trial name
- NCT07223307
- Testing
- MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Stanford University
Biliary Tract Cancer, Cholangiocarcinoma
Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer
The investigators design a prospective clinical study to explore the efficacy and safety of apatinib plus camrelizumab in pretreated patients with advanced biliary tract malignant tumors and to analyze potential biomarkers of…
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Biomarker, Hepatobiliary Neoplasm
- Trial name
- ACABC (NCT04642664)
- Testing
- Apatinib plus Camrelizumab
- Where
- 2 sites in China
- Volunteers
- 22 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Colorectal Carcinoma (mCRC), Metastatic Liver Cancer
Streamlining Radioembolization for CCC and Metastatic Liver Cancer
TARE uses radioactive microspheres (20-60 μm), which are trapped in tumors due to abnormal vasculature, while normal liver sinusoids (≤15 μm) prevent their passage.
- Conditions
- Metastatic Colorectal Carcinoma (mCRC), Metastatic Liver Cancer, Cholangiocarcinoma
- Trial name
- ISTAR-03 (NCT07043387)
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
- Trial name
- NCT07020221
- Testing
- VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 616 people
- Sponsor
- Verastem, Inc.
Cholangiocarcinoma
Advanced or Metastatic Cholangiocarcinoma
This is a single-arm, open, multicenter trial of carralizumab in combination with albumin paclitaxel and apatinib mesylate for the second-line treatment of patients with advanced or metastatic cholangiocarcinoma.
- Trial name
- NCT05653817
- Testing
- Carrilizumab, Albumin-bound paclitaxel, Apatinib
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.